Our results indicate that IL-21/IL-21R signaling also activates senescence signatures in AML LSCs leading us to conclude that the increased sensitivity of LSCs in the combination regimen is not due to the reversal of senescence in AML LSCs by IL-21 signaling. The gene discussed is IL21; the disease is acute myeloid leukemia.